438 Studies Now Enrolling
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle- Invasive Bladder Cancer
Study of Chemotherapy alone, Chemotherapy plus Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
| Sponsor: | Bristol Myers Squibb |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAS0581 |
| U.S. Govt. ID: | NCT03661320 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to test how well the drug works, safety, and side effects of the experimental drug called BMS-986205. BMS-986205 will be added to another cancer medicine called nivolumab plus chemotherapy for participants who have bladder cancer that has grown into the muscle wall of the bladder. These drugs will be compared to just chemotherapy.
This study is closed
Do You Qualify?
| Are you 18 years of age or older? | Yes | No |
| Have you been diagnosed with muscle invasive bladder cancer? | Yes | No |
| Are you eligible for radical cystectomy (removal of bladder, prostate, sperm sacs, uretrha, as necessary)? | Yes | No |
| Are you willing to undergo radical cystectomy while on study? | Yes | No |